What is GLP-1?
Glucagon-like peptide-1 — an endogenous incretin hormone that has become one of the most researched signalling molecules in metabolic science.
GLP-1 (glucagon-like peptide-1) is an incretin hormone — a class of gut-derived signalling molecules released in response to food intake. Produced primarily by L-cells in the small intestine and colon, GLP-1 plays a central role in glucose-dependent insulin secretion, appetite regulation, and gastric motility.
It is an endogenous peptide, meaning the human body produces it naturally. GLP-1 is cleaved from proglucagon by the enzyme prohormone convertase 1/3 and released into the bloodstream within minutes of eating. Its half-life in circulation is remarkably short — approximately two minutes — before it is degraded by dipeptidyl peptidase-4 (DPP-4).
This brief half-life is what makes GLP-1 both fascinating and challenging from a research perspective. The body's own GLP-1 acts fast and clears fast. The question that has driven two decades of pharmaceutical research is: what happens when you sustain that signal?
Biological Function
The Incretin Effect
The incretin effect describes the observation that oral glucose produces a significantly greater insulin response than intravenous glucose at matched blood glucose levels. This difference is mediated by gut hormones — principally GLP-1 and glucose-dependent insulinotropic polypeptide (GIP).
GLP-1 exerts its effects through the GLP-1 receptor (GLP-1R), which is expressed across multiple tissues:
Pancreas
Pancreatic Beta Cells
GLP-1 potentiates glucose-dependent insulin secretion. Unlike exogenous insulin administration, this mechanism is inherently self-limiting: as blood glucose normalises, the insulinotropic effect diminishes. This glucose-dependence is a defining characteristic of the incretin pathway.
CNS
Central Nervous System
GLP-1 receptors in the hypothalamus and brainstem mediate appetite signalling and satiety. This central action is a major area of current research interest.
GI Tract
Gastrointestinal Tract
GLP-1 slows gastric emptying, which moderates postprandial glucose excursions and contributes to prolonged satiety after meals.
Cardio
Cardiovascular System
GLP-1 receptors are present in cardiac and vascular tissue, a finding that has expanded the scope of incretin research beyond metabolic pathways.
Research Development
From Hormone to Research Tool
The therapeutic potential of GLP-1 was recognised early, but its two-minute half-life made it impractical as a direct treatment. The solution was to develop GLP-1 receptor agonists — compounds that activate the same receptor but resist DPP-4 degradation, extending their half-life from minutes to hours or days.
This approach drew on an unexpected source: the Gila monster. Exendin-4, a peptide found in the saliva of the Gila monster (*Heloderma suspectum*), shares approximately 53% sequence homology with human GLP-1 but is naturally resistant to DPP-4 degradation. This discovery, made by Dr John Eng in the early 1990s, became the foundation for the first GLP-1 receptor agonist.
The development pathway since then has been one of the most active in modern pharmacology:
1992
Exendin-4 Discovered
Isolated from Gila monster saliva by Dr John Eng. First identified GLP-1 receptor agonist of non-human origin. Naturally resistant to DPP-4 degradation.
2005
Exenatide (Byetta) Approved
Synthetic version of exendin-4. First GLP-1 receptor agonist approved for metabolic research applications. Twice-daily dosing.
2010
Liraglutide (Victoza) Approved
Modified human GLP-1 sequence with 97% homology. Fatty acylation extends half-life to approximately 13 hours, enabling once-daily dosing.
2017
Semaglutide (Ozempic) Approved
Further structural modifications extend half-life to approximately one week. Once-weekly dosing. Significant body of clinical trial data.
2022
Tirzepatide (Mounjaro) Approved
Dual GLP-1/GIP receptor agonist. First compound to engage both incretin receptors simultaneously. Represents the next generation of incretin-based research.
2023–26
Triple Agonists Enter Late-Stage Trials
Retatrutide and similar compounds engage GLP-1, GIP, and glucagon receptors simultaneously. Multiple Phase 3 trials underway with Australian research sites participating.
Research Landscape
Incretin Research in Australia
Australian research institutions are actively contributing to the global understanding of GLP-1 biology. The Baker Heart and Diabetes Institute in Melbourne has conducted multiple GLP-1 receptor agonist trials, and Australian hospital networks — including Royal Brisbane and Women's Hospital, The Alfred, and Fiona Stanley Hospital in Perth — are participating in large-scale clinical studies involving incretin-based compounds.
The University of Sydney's Charles Perkins Centre is a notable hub for metabolic research, with direct involvement in clinical trials investigating GLP-1, GIP, and glucagon receptor agonists. Across Australia, clinical trial sites span every major state and territory, reflecting the breadth of local research interest in incretin pathways.
This growing body of Australian research data contributes to the international evidence base and provides local context for the scientific community studying metabolic signalling pathways.
Beyond GLP-1
The Multi-Agonist Era
The evolution from single-target GLP-1 receptor agonists to multi-receptor agonists represents a significant shift in metabolic research strategy. While GLP-1 receptor activation alone produces meaningful biological effects, engaging additional receptors — particularly GIP and glucagon — appears to produce synergistic outcomes that exceed the sum of individual receptor activation.
Tirzepatide demonstrated the dual-agonist concept by simultaneously targeting GLP-1 and GIP receptors. Retatrutide extends this further by adding glucagon receptor engagement, creating a triple-agonist profile that is currently the subject of extensive Phase 3 investigation.
This multi-agonist approach reflects a deeper understanding of incretin biology — the recognition that metabolic regulation involves multiple overlapping signalling pathways, and that the most significant research advances may come from engaging several of these pathways simultaneously.
All products are research compounds intended for laboratory research use only. Not for human or veterinary use. Kinetic Labs does not provide dosing guidance, therapeutic recommendations, or medical advice of any kind.